Immune Design

We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Our two primary product candidates, CMB305 and G100, utilize distinct immuno-oncology approaches that, we believe, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action.

Type
Public
HQ
Seattle, US
Founded
2008
Size (employees)
50 (est)+22%
Immune Design was founded in 2008 and is headquartered in Seattle, US

Immune Design Office Locations

Immune Design has offices in Seattle and South San Francisco
Seattle, US (HQ)
310 1616 Eastlake Ave E
South San Francisco, US
250 601 Gateway Blvd

Immune Design Data and Metrics

Immune Design Financial Metrics

Numbers are in $, USD

Market capitalization (26-May-2017)

204.6 m

Closing share price (26-May-2017)

8.1
Immune Design's current market capitalization is $204.6 m.

Immune Design Operating Metrics

FY, 2016

Phase I Trials

1

Phase II Trials

3

Phase Preclinical

2

Patents (US)

16

Patents (foreign)

19

Immune Design Market Value History

Immune Design News and Updates

Immune Design Company Life and Culture

You may also be interested in